CO71 Faricimab Versus Standard of Care in Naive Neovascular Age-Related Macular Degeneration Patients: An Indirect Treatment Comparison Using Individual Level Data

To evaluate the potential benefit of faricimab, a new targeting vascular endothelial growth factor A (VEGF-A) and Angiopoietin-2, versus the current intravitreal (IV) a-VEGF SoC in nAMD patients.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: P. Lanzetta, M.C. Parravano, M. Nicol ò, G. Staurenghi, F. Viola, C. Galeone, L. Bianchino, E. Sicari, G. Villa, S. Vujosevic Source Type: research